Copyright
©The Author(s) 2019.
World J Gastroenterol. Mar 14, 2019; 25(10): 1266-1277
Published online Mar 14, 2019. doi: 10.3748/wjg.v25.i10.1266
Published online Mar 14, 2019. doi: 10.3748/wjg.v25.i10.1266
Table 1 Clinical characteristics of the pediatric Crohn’s disease patients included in the study (n = 53) n (%)
| Clinical characteristics of the pediatric Crohn’s disease | |
| Males | 36 (68) |
| Age years (median, IQR) | 14.9 (11.9-16.0) |
| Age at diagnosis years (median, IQR) | 10.9 (8.3-13.1) |
| Duration of disease years (median, IQR) | 3.0 (1.3-5.1) |
| Concomitant immunosuppressant | |
| Azathioprine | 27 (51) |
| Methotrexate | 19 (36) |
| None | 7 (13) |
| Previous IBD related surgery | |
| Perianal surgery | 1 (2) |
| Resectional surgery | 6 (11) |
| Crohn’s disease: Age at diagnosis (Paris classification) | |
| A1a: 0-< 10 yr | 20 (38) |
| A1b: 10-< 17 yr | 33 (62) |
| Crohn’s disease: Location (Paris classification) | |
| L1 | 5 (9) |
| L2 | 22 (42) |
| L3 | 26 (49) |
| L4 | 35 (66) |
| Crohn’s disease: Behaviour (Paris classification) | |
| B1: non-stricturing, non-penetrating | 31 (59) |
| B2: stricturing | 12 (23) |
| B3: penetrating | 7 (13) |
| B2B3: penetrating and structuring | 3 (5) |
| P: Perianal disease | 17 (32) |
| Crohn’s disease: Growth impairment (Paris classification) | |
| Evidence of growth delay | 0 (0) |
| Infliximab dosing | |
| Interval between infliximab doses (wk), mean (range) | 7 (4-8) |
| Mean dose (mg/kg) | 6.8 |
- Citation: Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol 2019; 25(10): 1266-1277
- URL: https://www.wjgnet.com/1007-9327/full/v25/i10/1266.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i10.1266